MedTrace Logo

A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK

NCT02836483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2020-02-06

No results posted yet for this study

Summary

A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.

Conditions

  • Pulmonary Tuberculosis

Interventions

DRUG

LCB01-0371 800mg, QD

Oral administration

DRUG

LCB01-0371 400mg, BID

Oral administration

DRUG

LCB01-0371 800mg, BID

Oral administration

DRUG

Tubes 3~5Tablet, QD

Oral administration

DRUG

Zyvox 600mg, BID

Oral administration

DRUG

LCB01-0371 1200mg, QD

Oral administration

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • T.S Sim, M.D., Ph.D · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-10
Primary Completion
2019-07-01
Completion
2019-07-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836483 on ClinicalTrials.gov